In 1998, Douni and Kollias [39] reported that mice transgenic for the human TNFR2 developed a severe inflammatory syndrome, including inflammatory liver disease even in the absence of endogenous TNFR1, which supported the notion that TNFR2 primarily drives inflammation by increased NFκB activation. The gene discussed is TNFRSF1B; the disease is liver disorder.